CU20200007A7 - Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación - Google Patents
Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparaciónInfo
- Publication number
- CU20200007A7 CU20200007A7 CU2020000007A CU20200007A CU20200007A7 CU 20200007 A7 CU20200007 A7 CU 20200007A7 CU 2020000007 A CU2020000007 A CU 2020000007A CU 20200007 A CU20200007 A CU 20200007A CU 20200007 A7 CU20200007 A7 CU 20200007A7
- Authority
- CU
- Cuba
- Prior art keywords
- suspension
- colon cancer
- antiulcerous
- preparation
- microcrystalline cellulose
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010009944 Colon cancer Diseases 0.000 title abstract 2
- 230000000767 anti-ulcer Effects 0.000 title abstract 2
- 230000001767 chemoprotection Effects 0.000 title abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 title abstract 2
- 229940100692 oral suspension Drugs 0.000 title 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- 150000002191 fatty alcohols Chemical class 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 235000013871 bee wax Nutrition 0.000 abstract 1
- 239000012166 beeswax Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>Se revela una nueva composición farmacéutica consistente en una suspensión acuosa oral para la prevención y tratamiento de las úlceras gástricas y el cáncer de colon, así como el procedimiento para prepararla. Esta suspensión se caracteriza por contener un extracto purificado con los alcoholes grasos de la cera de abejas, celulosa microcristalina y excipientes aceptados por la industria farmacéutica. El método de preparación de esta suspensión se caracteriza porque el extracto de alcoholes grasos se somete a un proceso de disminución de tamaño de partícula a < 1, 5 micrómetros en presencia de un agente emulsionante a > 1000 rpm; la mezcla de dicho ingrediente activo con celulosa microcristalina en la proporción y concentración en que se formulan, hace que estos componentes actúen de forma sinérgica, confiriéndole potentes efectos antiulcerosos y quimioprotectores a esta composición.</p>
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000007A CU24638B1 (es) | 2020-02-03 | 2020-02-03 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon |
AU2020427452A AU2020427452B2 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with anti-ulcerous and chemoprotective effect on colon cancer and preparation method thereof |
CA3169969A CA3169969A1 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with antiulcerous and chemoprotective effect on colon cancer and method for its preparation |
EP20917601.5A EP4101444A4 (en) | 2020-02-03 | 2020-12-14 | ORAL SUSPENSION WITH ANTI-ULCEROUS AND CHEOPROTECTIVE EFFECT ON COLON CANCER AND METHOD FOR ITS PREPARATION |
PCT/CU2020/050008 WO2021155871A1 (es) | 2020-02-03 | 2020-12-14 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación |
CN202080095526.6A CN115087432A (zh) | 2020-02-03 | 2020-12-14 | 具有抗溃疡和对结肠癌的化学保护性作用的口服悬浮液及其制备方法 |
KR1020227030797A KR20230129150A (ko) | 2020-02-03 | 2020-12-14 | 결장암에 대한 항궤양 및 화학보호 효과를 갖는 경구 현탁액 및 그의 제조 방법 |
JP2022547267A JP2023518659A (ja) | 2020-02-03 | 2020-12-14 | 結腸癌に対する抗潰瘍性及び化学的防御効果を有する経口懸濁液及びその調製方法 |
US17/797,022 US20230071637A1 (en) | 2020-02-03 | 2020-12-14 | Oral suspension with antiulcerous and chemoprotective effect on colon cancer and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000007A CU24638B1 (es) | 2020-02-03 | 2020-02-03 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20200007A7 true CU20200007A7 (es) | 2021-09-07 |
CU24638B1 CU24638B1 (es) | 2023-01-16 |
Family
ID=77199690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2020000007A CU24638B1 (es) | 2020-02-03 | 2020-02-03 | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230071637A1 (es) |
EP (1) | EP4101444A4 (es) |
JP (1) | JP2023518659A (es) |
KR (1) | KR20230129150A (es) |
CN (1) | CN115087432A (es) |
AU (1) | AU2020427452B2 (es) |
CA (1) | CA3169969A1 (es) |
CU (1) | CU24638B1 (es) |
WO (1) | WO2021155871A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22229A1 (es) * | 1992-09-29 | 1996-01-31 | Dalmer Lab Sa | Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la |
CU22412A1 (es) * | 1993-11-09 | 1996-01-31 | Dalmer Lab Sa | Una mezcla natural compuesta por alcoholes alifaticos primarios superiores obtenidos de la cera de abejas para el tratamiento de las ulceras gastricas y duodenales que presenta tambien actividad antiinflamatoria |
CN1125096A (zh) * | 1994-12-23 | 1996-06-26 | 戴默实验室股份公司 | 由来自蜂蜡的高级脂肪伯醇组成的天然混合物 |
CU22723A1 (es) * | 1997-04-02 | 2002-02-28 | Dalmer Lab Sa | Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos |
-
2020
- 2020-02-03 CU CU2020000007A patent/CU24638B1/es unknown
- 2020-12-14 CA CA3169969A patent/CA3169969A1/en active Pending
- 2020-12-14 EP EP20917601.5A patent/EP4101444A4/en active Pending
- 2020-12-14 US US17/797,022 patent/US20230071637A1/en active Pending
- 2020-12-14 JP JP2022547267A patent/JP2023518659A/ja active Pending
- 2020-12-14 AU AU2020427452A patent/AU2020427452B2/en active Active
- 2020-12-14 CN CN202080095526.6A patent/CN115087432A/zh active Pending
- 2020-12-14 WO PCT/CU2020/050008 patent/WO2021155871A1/es active Application Filing
- 2020-12-14 KR KR1020227030797A patent/KR20230129150A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CN115087432A (zh) | 2022-09-20 |
WO2021155871A1 (es) | 2021-08-12 |
EP4101444A1 (en) | 2022-12-14 |
CA3169969A1 (en) | 2021-08-12 |
JP2023518659A (ja) | 2023-05-08 |
AU2020427452A1 (en) | 2022-09-22 |
EP4101444A4 (en) | 2024-02-28 |
AU2020427452B2 (en) | 2023-11-23 |
CU24638B1 (es) | 2023-01-16 |
KR20230129150A (ko) | 2023-09-06 |
US20230071637A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
MX2012005677A (es) | Formulaciones parentales de derivados de gemcitabina. | |
AR070561A1 (es) | Anillos intravaginales monoliticos que comprenden progesterona y metodos para su fabricacion y uso | |
BRPI1012959A8 (pt) | Dispersoes solidas contendo um agente promotor de apoptose | |
BRPI0408256A (pt) | composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo | |
ES2529235T3 (es) | Formulaciones farmacéuticas que contienen palmitoil-etanolamida y estearoil-etanolamida | |
CL2017001913A1 (es) | Composición tópica curativa | |
EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
CU20200007A7 (es) | Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación | |
RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
AR114216A1 (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario | |
JP2006520331A5 (es) | ||
US11298393B2 (en) | Composition comprising a mixture of an extract and bentonite | |
JPWO2021003341A5 (es) | ||
TW201511766A (zh) | 用於增進男性性健康之方法及組合物 | |
DE202013005637U1 (de) | Mittel mit Tocotrienol bei Verbrennungen durch Sonne, radioaktive Strahlung oder Hitze | |
CL2013003137A1 (es) | Composición farmacéutica líquida oral que contiene divalproex sódico (2-15 % p/v de la composición), y uno o más excipientes, cuyo ph es mayor a 6; procedimiento de preparación de la composición que comprende: (a) mezclar hidróxido de sodio en agua purificada, (b) añadir divalproex sódico y excipientes; y (c) ajustar ph sobre 6. | |
FR2618677A1 (fr) | Composition pharmaceutique destinee a la prevention et au traitement des maladies bacteriennes ou virales | |
CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
EA202290122A1 (ru) | Фармацевтические композиции в форме геля, содержащие ксилоглюкан и спирты, для регулируемого высвобождения активных ингредиентов | |
JP2022514809A (ja) | ドライアイ症候群の治療におけるリポソーム点眼剤溶液およびその使用 | |
RU2010125503A (ru) | СОДЕРЖАЩАЯ КОМБИНАЦИЮ ЦЕОЛИТ/ВОДОРОСЛИ ИЛИ ЦЕОЛИТ/ЭМУЛЬСИЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа | |
ES2779525T3 (es) | Composición que comprende un éster de alfa-tocoferol para prevención y tratamiento de rinitis alérgica | |
BR112019028088A8 (pt) | Dispersão sólida amorfa de belinostate, processo de preparação da dispersão sólida amorfa de belinostate e composição farmacêutica | |
RU2780109C1 (ru) | Противовоспалительные глазные капли для домашних и сельскохозяйственных животных |